Who Paid My Doc
Sarah Ali
Infectious Disease Washington, DC Medical Doctor
NPI 1083848766 CMS profile 1296845
2333 Ontario Rd Nw, Washington, DC 20009
General payments
$280
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Sarah Ali of Washington, DC is reported in the CMS Open Payments database as having received $280 across 5 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 43rd percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $122 | 1 | |
| 2023 | General | $21 | 1 | |
| 2021 | General | $15 | 1 | |
| 2019 | General | $123 | 2 |
Beside peers
- Sarah Ali
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Sarah Ali were reported at $122. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Sarah Ali | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $123 | $190 | $60–$862 | $163 |
| 2020 | $0 | $124 | $32–$606 | $114 |
| 2021 | $15 | $148 | $38–$905 | $132 |
| 2022 | $0 | $166 | $50–$834 | $149 |
| 2023 | $21 | $171 | $57–$787 | $160 |
| 2024 | $0 | $176 | $52–$752 | $164 |
| 2025 | $122 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 23 drugsPart D claims
433
Drug cost
$244,358
Branded share of claims
31.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 19 | $73,409 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 15 | $51,989 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 11 | $41,668 | |
| Tivicay Dolutegravir Sodium | Brand | 11 | $24,747 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 11 | $24,143 | |
| Januvia Sitagliptin Phosphate | Brand | 11 | $14,520 | |
| Eliquis Apixaban | Brand | 11 | $6,527 | |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | Brand | 11 | $3,503 | |
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 27 | $821 | |
| Tamsulosin Hcl | Generic | 14 | $486 |
The 10 drugs with the highest cost, of 23 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Records
5 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in District of Columbia
Related records
Infectious Disease in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.